14 results
DEFC14A
ALKS
Alkermes plc
25 May 23
Proxy in contested solicitation
4:03pm
contributed to our ability to maintain rates of workplace accidents resulting in recordable injuries, and of accidents resulting in lost employee work time
PRER14A
ALKS
Alkermes plc
19 May 23
Preliminary revised proxy
5:23pm
contributed to our ability to maintain rates of workplace accidents resulting in recordable injuries, and of accidents resulting in lost employee work
PREC14A
ALKS
Alkermes plc
8 May 23
Preliminary proxy with contested solicitation
4:34pm
to maintain rates of workplace accidents resulting in recordable injuries, and of accidents resulting in lost employee work time, below U.S. Bureau
DEFC14A
iwmw3sls9wz7p6i5yd
6 Jun 22
Proxy in contested solicitation
5:29pm
PREC14A
gnovrk0xwll1a8kgfy4
26 May 22
Preliminary proxy with contested solicitation
5:29pm
8-K
EX-99.1
k3oqz448
1 Jun 21
Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder
7:09am
10-K
af60 pyqk
18 May 12
Annual report
12:00am
424B3
0m8t9ismky32pfal4
8 Mar 12
Prospectus supplement
12:00am
424B3
frvt7tkzwxw47e j7hv
8 Mar 12
Prospectus supplement
12:00am
- Prev
- 1
- Next